Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination with Antibody Therapies in Patients with Advanced Hematologic Cancers
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Molecular Pathogenesis of Plasma Cell Disorder
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Study Summary
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 29, 2024
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 26, 2024
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 21, 2024
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 8, 2024
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 7, 2024
A Phase II Trial of Tazemetostat Plus Mosunetuzumab In Untreated Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 7, 2024
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination with MGD019 in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 7, 2024
Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Cancer: A Non-interventional Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 29, 2024